You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾輝健康-B(6606.HK)上市首日大漲近200%!
格隆匯 02-18 09:34
格隆匯2月18日丨諾輝健康-B(6606.HK)上市首日高開185.07%後繼續上行,現報79.2港元,大漲197.07%,暫成交14億港元,最新總市值超331億港元。該股IPO定價為26.66港元,公開發售獲4133.19倍認購。公司於2015年11月成立,是中國癌症篩查市場的先行者和領導者,公司旗下的兩款結直腸癌篩查產品(常衞清和噗噗管)已獲得國家藥品監督管理局的批准,常衞清是中國首個且目前唯一一個獲得國家藥品監督管理局批准的癌症早篩產品。公司此次引入的基石投資者包括景順(Invesco)、清池資本、博裕資本、GIC、加皇環球資產管理(RBC)、Columbia Funds、Janus Henderson Funds、Rock Springs Capital、Worldwide Healthcare Trust PLC、LAV、Cormorant Global、HBC Asia Healthcare Opportunities VII LLC、Octagon Investments、Sage Partners、南方基金管理有限公司及E Fund(易方達)。作為基石投資者認購約1.24億美元股份。其中奧博資本(Worldwide Healthcare Trust PLC)、Rock Springs、禮來亞洲基金在諾輝健康之前的多輪融資中均有參與。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account